136 related articles for article (PubMed ID: 23477254)
1. [Characterization of influenza virus reassortants based on new donor strain A/HK/1/68/162/35(H3N2)].
Potapchuk MV; Repko IA; Sergeeva MV; Korotkov AV; Komissarov AB; Sandybaev NT; Cherviakova OV; Khaĭrullin VM; Tsybalova LM
Vopr Virusol; 2012; 57(6):42-6. PubMed ID: 23477254
[TBL] [Abstract][Full Text] [Related]
2. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses.
Shi H; Liu XF; Zhang X; Chen S; Sun L; Lu J
Vaccine; 2007 Oct; 25(42):7379-84. PubMed ID: 17870216
[TBL] [Abstract][Full Text] [Related]
3. Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus.
Worobey M; Han GZ; Rambaut A
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8107-12. PubMed ID: 24778238
[TBL] [Abstract][Full Text] [Related]
4. [High-yield reassortant virus containing hemagglutinin and neuraminidase genes of pandemic influenza A/Moscowl/01/2009 (H1N1) virus].
Ignat'eva AV; Rudneva IA; Timofeeva TA; Shilov AA; Zaberezhnyĭ AD; Aliper TI; Kaverin NV; L'vov DK
Vopr Virusol; 2011; 56(4):9-14. PubMed ID: 21899062
[TBL] [Abstract][Full Text] [Related]
5. [Genome composition analysis of the reassortant influenza viruses used in seasonal and pandemic live attenuated influenza vaccine].
Kiseleva IV; Voeten JT; Teley LC; Larionova NV; Dubrovina IA; Berdygulova ZhA; Bazhenova EA; van den Bosch H; Heldens JG; Rudenko LG
Mol Gen Mikrobiol Virusol; 2011; (4):29-36. PubMed ID: 22312898
[TBL] [Abstract][Full Text] [Related]
6. Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines.
Nakowitsch S; Waltenberger AM; Wressnigg N; Ferstl N; Triendl A; Kiefmann B; Montomoli E; Lapini G; Sergeeva M; Muster T; Romanova JR
Biotechnol J; 2014 Mar; 9(3):405-14. PubMed ID: 24323790
[TBL] [Abstract][Full Text] [Related]
7. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential.
Desheva JA; Lu XH; Rekstin AR; Rudenko LG; Swayne DE; Cox NJ; Katz JM; Klimov AI
Vaccine; 2006 Nov; 24(47-48):6859-66. PubMed ID: 17050041
[TBL] [Abstract][Full Text] [Related]
8. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
Lei H; Peng X; Jiao H; Zhao D; Ouyang J
Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
[TBL] [Abstract][Full Text] [Related]
9. Recommended composition of influenza vaccines for use in the 2012 southern hemisphere influenza season.
Wkly Epidemiol Rec; 2011 Oct; 86(42):457-68. PubMed ID: 22046594
[No Abstract] [Full Text] [Related]
10. Recommended composition of influenza virus vaccines for use in the 2007-2008 influenza season.
Wkly Epidemiol Rec; 2007 Mar; 82(9):69-74. PubMed ID: 17333570
[No Abstract] [Full Text] [Related]
11. Recommended composition of influenza virus vaccines for use in the 2016–2017 northern hemisphere influenza season.
Wkly Epidemiol Rec; 2016 Mar; 91(10):121-32. PubMed ID: 26971356
[No Abstract] [Full Text] [Related]
12. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.
Koudstaal W; Hartgroves L; Havenga M; Legastelois I; Ophorst C; Sieuwerts M; Zuijdgeest D; Vogels R; Custers J; de Boer-Luijtze E; de Leeuw O; Cornelissen L; Goudsmit J; Barclay W
Vaccine; 2009 Apr; 27(19):2588-93. PubMed ID: 19428865
[TBL] [Abstract][Full Text] [Related]
13. [Characterization of cold-adapted influenza strain A/HongKong/1/68/162/35 as a potential donor of attenuation and high reproduction].
Tsybalova LM; Gorev NE; Potapchuk MV; Repko IA; Korotkov AV; Sergeeva MV; Komissarov AB; Pisareva MM; Kuznetsov VV; Grudinin MP; Kiselev OI
Vopr Virusol; 2012; 57(6):13-7. PubMed ID: 23477248
[TBL] [Abstract][Full Text] [Related]
14. Dose-response assessment for influenza A virus based on data sets of infection with its live attenuated reassortants.
Watanabe T; Bartrand TA; Omura T; Haas CN
Risk Anal; 2012 Mar; 32(3):555-65. PubMed ID: 21977924
[TBL] [Abstract][Full Text] [Related]
15. Caspase-1 deficient mice are more susceptible to influenza A virus infection with PA variation.
Huang CH; Chen CJ; Yen CT; Yu CP; Huang PN; Kuo RL; Lin SJ; Chang CK; Shih SR
J Infect Dis; 2013 Dec; 208(11):1898-905. PubMed ID: 23901080
[TBL] [Abstract][Full Text] [Related]
16. [Restriction analysis of genome composition of live influenza vaccine].
Kiseleva IV; Larionova NV; Teley LC; Rudenko LG
Vopr Virusol; 2011; 56(3):28-32. PubMed ID: 21786624
[TBL] [Abstract][Full Text] [Related]
17. Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses.
Price GE; Soboleski MR; Lo CY; Misplon JA; Quirion MR; Houser KV; Pearce MB; Pappas C; Tumpey TM; Epstein SL
PLoS One; 2010 Oct; 5(10):e13162. PubMed ID: 20976273
[TBL] [Abstract][Full Text] [Related]
18. Generation and evaluation of the trivalent inactivated reassortant vaccine using human, avian, and swine influenza A viruses.
Du N; Li W; Li Y; Liu S; Sui Y; Qu Z; Wang Y; Du Y; Xu B
Vaccine; 2008 Jun; 26(23):2912-8. PubMed ID: 18448208
[TBL] [Abstract][Full Text] [Related]
19. Cross-Reactive Neuraminidase-Inhibiting Antibodies Elicited by Immunization with Recombinant Neuraminidase Proteins of H5N1 and Pandemic H1N1 Influenza A Viruses.
Liu WC; Lin CY; Tsou YT; Jan JT; Wu SC
J Virol; 2015 Jul; 89(14):7224-34. PubMed ID: 25948745
[TBL] [Abstract][Full Text] [Related]
20. Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season.
Wkly Epidemiol Rec; 2011 Mar; 86(10):86-90. PubMed ID: 21395187
[No Abstract] [Full Text] [Related]
[Next] [New Search]
